Hypothalamic-pituitary-adrenal axis activity and early onset of cannabis use

被引:58
作者
Huizink, Anja C.
Ferdinand, Robert F.
Ormel, Johan
Verhulst, Frank C.
机构
[1] Sophia Childrens Univ Hosp, Erasmus Med Ctr Rotterdam, Dept Child & Adolescent Psychiat, NL-3000 CB Rotterdam, Netherlands
[2] Univ Groningen, Dept Psychiat, Med Ctr, Groningen, Netherlands
[3] Univ Groningen, Grad Sch Behav Cognit Neurosci, Med Ctr, Groningen, Netherlands
关键词
adolescents; cannabis; cortisol; early onset; HPA axis;
D O I
10.1111/j.1360-0443.2006.01570.x
中图分类号
R194 [卫生标准、卫生检查、医药管理];
学科分类号
摘要
Aims To identify early onset cannabis users by measuring basal hypothalamic-pituitary-adrenal (HPA) axis activity, which may be a risk factor for early onset substance use when showing low activity. Design In a prospective cohort study, adolescents who initiated cannabis use at an early age (9-12 years), those who initiated at a later age ( 13 14 years) and those who did not use cannabis by the age of 14 were compared with respect to HPA axis activity. Setting and participants Data were used from the first and second assessment wave of the TRacking Adolescents' Individual Lives Survey ( TRAILS), that included 1768 Dutch young adolescents aged 10-12 years who were followed-up across a period of 2 years. Measurements Cortisol was measured in saliva samples at awakening, 30 minutes later and at 8 p. m. at age 10-12. Self-reported age at first cannabis use was used. Findings The early onset group had lower cortisol levels 30 minutes after awakening than the late onset group ( OR = 0.93, 95% CI: 0.86-0.99). Furthermore, compared to non-users, the early and late onset cannabis users had higher levels of cortisol at 8 p. m. ( OR = 1.25, 95% CI: 1.03-1.53 and OR = 1.21, 95% CI: 1.01-1.45, respectively). Conclusions Some evidence was found for HPA axis hypo-activity at awakening in adolescents with early onset of cannabis use compared to late onset users, which might indicate an increased risk for early onset users of seeking stimulation to restore arousal levels by using substances.
引用
收藏
页码:1581 / 1588
页数:8
相关论文
共 48 条
[1]  
Aardal E, 1995, EUR J CLIN CHEM CLIN, V33, P927
[2]   Heritability of cortisol levels: review and simultaneous analysis of twin studies [J].
Bartels, M ;
Van den Berg, M ;
Sluyter, F ;
Boomsma, DI ;
de Geus, EJC .
PSYCHONEUROENDOCRINOLOGY, 2003, 28 (02) :121-137
[3]  
BROOKSGUNN J, 1987, CHILD DEV, V58, P829, DOI 10.2307/1130220
[4]   CHRONIC ESTROGEN-INDUCED ALTERATIONS IN ADRENOCORTICOTROPIN AND CORTICOSTERONE SECRETION, AND GLUCOCORTICOID RECEPTOR-MEDIATED FUNCTIONS IN FEMALE RATS [J].
BURGESS, LH ;
HANDA, RJ .
ENDOCRINOLOGY, 1992, 131 (03) :1261-1269
[5]   The awakening cortisol response: Methodological issues and significance [J].
Clow, A ;
Thorn, L ;
Evans, P ;
Hucklebridge, F .
STRESS-THE INTERNATIONAL JOURNAL ON THE BIOLOGY OF STRESS, 2004, 7 (01) :29-37
[6]   Hormonal and behavioral homeostasis in boys at risk for substance abuse [J].
Dawes, MA ;
Dorn, LD ;
Moss, HB ;
Yao, JK ;
Kirisci, L ;
Ammerman, RT ;
Tarter, RE .
DRUG AND ALCOHOL DEPENDENCE, 1999, 55 (1-2) :165-176
[7]   Evaluation of non-response bias in mental health determinants and outcomes in a large sample of pre-adolescents [J].
de Winter, AF ;
Oldehinkel, AJ ;
Veenstra, R ;
Brunnekreef, JA ;
Verhulst, FC ;
Ormel, J .
EUROPEAN JOURNAL OF EPIDEMIOLOGY, 2005, 20 (02) :173-181
[8]   PERCEPTIONS OF PUBERTY - ADOLESCENT, PARENT, AND HEALTH-CARE PERSONNEL [J].
DORN, LD ;
SUSMAN, EJ ;
NOTTELMANN, ED ;
INOFFGERMAIN, G ;
CHROUSOS, GP .
DEVELOPMENTAL PSYCHOLOGY, 1990, 26 (02) :322-329
[9]   Effects of coadministration of cannabinoids and morphine on nociceptive behaviour, brain monoamines and HPA axis activity in a rat model of persistent pain [J].
Finn, DP ;
Beckett, SRG ;
Roe, CH ;
Madjd, A ;
Fone, KCF ;
Kendall, DA ;
Marsden, CA ;
Chapman, V .
EUROPEAN JOURNAL OF NEUROSCIENCE, 2004, 19 (03) :678-686
[10]   Low cortisol and a flattening of expected daytime rhythm: Potential indices of risk in human development [J].
Gunnar, MR ;
Vazquez, DM .
DEVELOPMENT AND PSYCHOPATHOLOGY, 2001, 13 (03) :515-538